Alfred H Schinkel

List of Publications by Year
in descending order

157	16,279	19657 61	16183 124
papers	citations	h-index	g-index

157	157	157	11937
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Population Pharmacokinetic Modelling to Support the Evaluation of Preclinical Pharmacokinetic Experiments with Lorlatinib. Journal of Pharmaceutical Sciences, 2022, 111, 495-504.	3.3	2
2	ABCB1 and ABCG2 limit brain penetration and, together with CYP3A4, total plasma exposure of abemaciclib and its active metabolites. Pharmacological Research, 2022, 178, 105954.	7.1	9
3	Rifampin and ritonavir increase oral availability and elacridar enhances overall exposure and brain accumulation of the NTRK inhibitor larotrectinib. European Journal of Pharmaceutics and Biopharmaceutics, 2022, 170, 197-207.	4.3	0
4	Drug Transporters ABCB1 (P-gp) and OATP, but not Drug-Metabolizing Enzyme CYP3A4, Affect the Pharmacokinetics of the Psychoactive Alkaloid Ibogaine and its Metabolites. Frontiers in Pharmacology, 2022, 13, 855000.	3.5	2
5	ABCB1 limits brain exposure of the KRASG12C inhibitor sotorasib, whereas ABCB1, CYP3A, and possibly OATP1a/1b restrict its oral availability. Pharmacological Research, 2022, 178, 106137.	7.1	4
6	Predictiveness of the Human-CYP3A4-Transgenic Mouse Model (Cyp3aXAV) for Human Drug Exposure of CYP3A4-Metabolized Drugs. Pharmaceuticals, 2022, 15, 860.	3.8	3
7	ABCB1 restricts brain accumulation of the novel RORÎ³ agonist cintirorgon, while OATP1A/1B and CYP3A limit its oral availability. European Journal of Pharmaceutics and Biopharmaceutics, 2022, 177, 135-146.	4.3	1
8	Extrahepatic metabolism of ibrutinib. Investigational New Drugs, 2021, 39, 1-14.	2.6	12
9	Pharmacokinetics of docetaxel and ritonavir after oral administration of ModraDoc006/r in patients with prostate cancer versus patients with other advanced solid tumours. Cancer Chemotherapy and Pharmacology, 2021, 87, 855-869.	2.3	12
10	ABCB1 and ABCG2 Restrict Brain and Testis Accumulation and, Alongside CYP3A, Limit Oral Availability of the Novel TRK Inhibitor Selitrectinib. Molecular Cancer Therapeutics, 2021, 20, 1173-1182.	4.1	6
11	The role of drug efflux and uptake transporters ABCB1 (P-gp), ABCG2 (BCRP) and OATP1A/1B and of CYP3A4 in the pharmacokinetics of the CDK inhibitor milciclib. European Journal of Pharmaceutical Sciences, 2021, 159, 105740.	4.0	5
12	Quantification of KRAS inhibitor sotorasib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2021, 1174, 122718.	2.3	11
13	Simultaneous quantification of abemaciclib and its active metabolites in human and mouse plasma by UHPLCâ€“MS/MS. Journal of Pharmaceutical and Biomedical Analysis, 2021, 203, 114225.	2.8	10
14	ABCB1 and ABCG2, but not CYP3A4 limit oral availability and brain accumulation of the RET inhibitor pralsetinib. Pharmacological Research, 2021, 172, 105850.	7.1	6
15	The suitability of oral diacetylmorphine in treatment-refractory patients with heroin dependence: A scoping review. Drug and Alcohol Dependence, 2021, 227, 108984.	3.2	12
16	ABCB1 and ABCG2 Control Brain Accumulation and Intestinal Disposition of the Novel ROS1/TRK/ALK Inhibitor Repotrectinib, While OATP1A/1B, ABCG2, and CYP3A Limit Its Oral Availability. Pharmaceutics, 2021, 13, 1761.	4.5	6
17	P-Glycoprotein (ABCB1/MDR1) and BCRP (ABCG2) Limit Brain Accumulation and Cytochrome P450-3A (CYP3A) Restricts Oral Exposure of the RET Inhibitor Selpercatinib (RETEVMO). Pharmaceuticals, 2021, 14, 1087.	3.8	2
18	P-Glycoprotein (ABCB1/MDR1) Controls Brain Penetration and Intestinal Disposition of the PARP1/2 Inhibitor Niraparib. Molecular Pharmaceutics, 2021, 18, 4371-4384.	4.6	6

#	Article	IF	Citations
19	Pâ€glycoprotein (MDR1/ABCB1) controls brain accumulation and intestinal disposition of the novel TGFâ€Î²2 signaling pathway inhibitor galunisertib. International Journal of Cancer, 2020, 146, 1631-1642.	5.1	7
20	P-glycoprotein (ABCB1/MDR1) limits brain accumulation and Cytochrome P450-3A (CYP3A) restricts oral availability of the novel FGFR4 inhibitor fisogatinib (BLU-554). International Journal of Pharmaceutics, 2020, 573, 118842.	5.2	10
21	Clinical Pharmacokinetics and Pharmacodynamics of the Cyclin-Dependent Kinase 4 and 6 Inhibitors Palbociclib, Ribociclib, and Abemaciclib. Clinical Pharmacokinetics, 2020, 59, 1501-1520.	3.5	43
22	No relation between docetaxel administration route and highâ€grade diarrhea incidence. Pharmacology Research and Perspectives, 2020, 8, e00633.	2.4	9
23	Development and validation of an LC-MS/MS method for the quantitative analysis of milciclib in human and mouse plasma, mouse tissue homogenates and tissue culture medium. Journal of Pharmaceutical and Biomedical Analysis, 2020, 190, 113516.	2.8	6
24	Quantitative bioanalytical assay for the selective RET inhibitors selpercatinib and pralsetinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2020, 1147, 122131.	2.3	8
25	Human organic anion transporting polypeptide (OATP) 1B3 and mouse OATP1A/1B affect liver accumulation of Ochratoxin A in mice. Toxicology and Applied Pharmacology, 2020, 401, 115072.	2.8	8
26	OATP1A/1B, CYP3A, ABCB1, and ABCG2 limit oral availability of the NTRK inhibitor larotrectinib, while ABCB1 and ABCG2 also restrict its brain accumulation. British Journal of Pharmacology, 2020, 177, 3060-3074.	5.4	14
27	Inhibition of Hepatic Bile Acid Uptake by Myrcludex B Promotes Glucagon-Like Peptide-1 Release and Reduces Obesity. Cellular and Molecular Gastroenterology and Hepatology, 2020, 10, 451-466.	4.5	15
28	Brain accumulation of tivozanib is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	5.2	11
29	Bioanalytical assay for the new-generation ROS1/TRK/ALK inhibitor repotrectinib in mouse plasma and tissue homogenate using liquid chromatography-tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2020, 1144, 122098.	2.3	7
30	P-glycoprotein Limits Ribociclib Brain Exposure and CYP3A4 Restricts Its Oral Bioavailability. Molecular Pharmaceutics, 2019, 16, 3842-3852.	4.6	30
31	Oral coadministration of elacridar and ritonavir enhances brain accumulation and oral availability of the novel ALK/ROS1 inhibitor lorlatinib. European Journal of Pharmaceutics and Biopharmaceutics, 2019, 136, 120-130.	4.3	17
32	Metabolome Analysis Reveals Dermal Histamine Accumulation in Murine Dermatitis Provoked by Genetic Deletion of P-Glycoprotein and Breast Cancer Resistance Protein. Pharmaceutical Research, 2019, 36, 158.	3.5	12
33	Development and validation of a bioanalytical method for the quantification of the CDK4/6 inhibitors abemaciclib, palbociclib, and ribociclib in human and mouse matrices using liquid chromatography-tandem mass spectrometry. Analytical and Bioanalytical Chemistry, 2019, 411, 5331-5345.	3.7	47
34	Brain accumulation of osimertinib and its active metabolite AZ5104 is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein). Pharmacological Research, 2019, 146, 104297.	7.1	29
35	Bioanalytical assay for the novel TRK inhibitor selitrectinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2019, 1122-1123, 78-82.	2.3	5
36	Quantification of FGFR4 inhibitor BLU-554 in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2019, 1110-1111, 116-123.	2.3	9

#	Article	IF	Citations
37	P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) limit brain accumulation of the FLT3 inhibitor quizartinib in mice. International Journal of Pharmaceutics, 2019, 556, 172-180.	5.2	10
38	Bioanalytical assay for the quantification of the ALK inhibitor lorlatinib in mouse plasma using liquid chromatography-tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1083, 204-208.	2.3	16
39	P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) affect brain accumulation and intestinal disposition of encorafenib in mice. Pharmacological Research, 2018, 129, 414-423.	7.1	31
40	P-glycoprotein and breast cancer resistance protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability. Pharmacological Research, 2018, 137, 47-55.	7.1	25
41	P-Glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Brutonâ€™s Tyrosine Kinase Inhibitor Ibrutinib, While Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability. Molecular Pharmaceutics, 2018, 15, 5124-5134.	4.6	15
42	Quantitative bioanalytical assay for the tropomyosin receptor kinase inhibitor larotrectinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2018, 1102-1103, 167-172.	2.3	10
43	Pâ€glycoprotein (MDR1/ABCB1) restricts brain accumulation and cytochrome P450â€3A (CYP3A) limits oral availability of the novel ALK/ROS1 inhibitor lorlatinib. International Journal of Cancer, 2018, 143, 2029-2038.	5.1	32
44	Bioanalytical liquid chromatography-tandem mass spectrometric assay for the quantification of the ALK inhibitors alectinib, brigatinib and lorlatinib in plasma and mouse tissue homogenates. Journal of Pharmaceutical and Biomedical Analysis, 2018, 161, 136-143.	2.8	22
45	P-Glycoprotein in skin contributes to transdermal absorption of topical corticosteroids. International Journal of Pharmaceutics, 2017, 521, 365-373.	5.2	18
46	Hepatic uptake of conjugated bile acids is mediated by both sodium taurocholate cotransporting polypeptide and organic anion transporting polypeptides and modulated by intestinal sensing of plasma bile acid levels in mice. Hepatology, 2017, 66, 1631-1643.	7.3	100
47	Ochratoxin A transport by the human breast cancer resistance protein (BCRP), multidrug resistance protein 2 (MRP2), and organic anion-transporting polypeptides 1A2, 1B1 and 2B1. Toxicology and Applied Pharmacology, 2017, 329, 18-25.	2.8	13
48	Breast cancer resistance protein (BCRP/ABCG2) and P-glycoprotein (P-gp/ABCB1) transport afatinib and restrict its oral availability and brain accumulation. Pharmacological Research, 2017, 120, 43-50.	7.1	43
49	Brain Accumulation of Ponatinib and Its Active Metabolite, N-Desmethyl Ponatinib, Is Limited by P-Glycoprotein (P-GP/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2). Molecular Pharmaceutics, 2017, 14, 3258-3268.	4.6	25
50	Liquid chromatography-tandem mass spectrometric assay for the quantitative determination of the tyrosine kinase inhibitor quizartinib in mouse plasma using salting-out liquid-liquid extraction. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2017, 1061-1062, 300-305.	2.3	7
51	What next? Preferably development of drugs that are no longer transported by the ABCB1 and ABCG2 efflux transporters. Pharmacological Research, 2017, 123, 144.	7.1	4
52	Ritonavir inhibits intratumoral docetaxel metabolism and enhances docetaxel antitumor activity in an immunocompetent mouse breast cancer model. International Journal of Cancer, 2016, 138, 758-769.	5.1	26
53	The impact of Organic Anion-Transporting Polypeptides (OATPs) on disposition and toxicity of antitumor drugs: Insights from knockout and humanized mice. Drug Resistance Updates, 2016, 27, 72-88.	14.4	46
54	Liquid chromatographyâ€“tandem mass spectrometric assay for the tyrosine kinase inhibitor afatinib in mouse plasma using salting-out liquidâ€“liquid extraction. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2016, 1012-1013, 118-123.	2.3	18

#	Article	IF	Citations
55	Liquid chromatographyâ€“tandem mass spectrometric assay for the simultaneous determination of the irreversible BTK inhibitor ibrutinib and its dihydrodiol-metabolite in plasma and its application in mouse pharmacokinetic studies. Journal of Pharmaceutical and Biomedical Analysis, 2016, 118, 123-131.	2.8	39
56	Apical ABC Transporters and Cancer Chemotherapeutic Drug Disposition. Advances in Cancer Research, 2015, 125, 1-41.	5.0	83
57	Brain and Testis Accumulation of Regorafenib is Restricted by Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1). Pharmaceutical Research, 2015, 32, 2205-2216.	3.5	53
58	Breast Cancer Resistance Protein (BCRP/ABCG2) and P-glycoprotein (P-GP/ABCB1) Restrict Oral Availability and Brain Accumulation of the PARP Inhibitor Rucaparib (AG-014699). Pharmaceutical Research, 2015, 32, 37-46.	3.5	79
59	Hepatocellular Shuttling and Recirculation of Sorafenib-Glucuronide Is Dependent on Abcc2, Abcc3, and Oatp1a/1b. Cancer Research, 2015, 75, 2729-2736.	0.9	59
60	Preclinical Mouse Models To Study Human OATP1B1- and OATP1B3-Mediated Drugâ€“Drug Interactions in Vivo. Molecular Pharmaceutics, 2015, 12, 4259-4269.	4.6	32
61	Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2). Pharmacological Research, 2015, 102, 200-207.	7.1	59
62	P-glycoprotein, CYP3A, and Plasma Carboxylesterase Determine Brain Disposition and Oral Availability of the Novel Taxane Cabazitaxel (Jevtana) in Mice. Molecular Pharmaceutics, 2015, 12, 3714-3723.	4.6	20
63	Human OATP1B1, OATP1B3 and OATP1A2 can mediate thein vivouptake and clearance of docetaxel. International Journal of Cancer, 2015, 136, 225-233.	5.1	58
64	Down-regulation of OATP1B proteins correlates with hyperbilirubinemia in advanced cholestasis. International Journal of Clinical and Experimental Pathology, 2015, 8, 5252-62.	0.5	6
65	Evaluation of Organic Anion Transporting Polypeptide 1B1 and 1B3 Humanized Mice as a Translational Model to Study the Pharmacokinetics of Statins. Drug Metabolism and Disposition, 2014, 42, 1301-1313.	3.3	31
66	Liquid chromatographyâ€“tandem mass spectrometric assay for the multikinase inhibitor regorafenib in plasma. Biomedical Chromatography, 2014, 28, 1366-1370.	1.7	22
67	In vivo disposition of doxorubicin is affected by mouse Oatp1a/1b and human OATP1A/1B transporters. International Journal of Cancer, 2014, 135, 1700-1710.	5.1	43
68	OATP1A/1B Transporters Affect Irinotecan and SN-38 Pharmacokinetics and Carboxylesterase Expression in Knockout and Humanized Transgenic Mice. Molecular Cancer Therapeutics, 2014, 13, 492-503.	4.1	33
69	Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the Pâ€glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. International Journal of Cancer, 2014, 134, 1484-1494.	5.1	127
70	P-Glycoprotein, CYP3A, and Plasma Carboxylesterase Determine Brain and Blood Disposition of the mTOR Inhibitor Everolimus (Afinitor) in Mice. Clinical Cancer Research, 2014, 20, 3133-3145.	7.0	29
71	Bcrp1;Mdr1a/b;Mrp2 Combination Knockout Mice: Altered Disposition of the Dietary Carcinogen PhIP (2-Amino-1-Methyl-6-Phenylimidazo[4,5-b]Pyridine) and Its Genotoxic Metabolites. Molecular Pharmacology, 2014, 85, 520-530.	2.3	22
72	Liquid chromatographyâ€“tandem mass spectrometric assay for the PARP inhibitor rucaparib in plasma. Journal of Pharmaceutical and Biomedical Analysis, 2014, 88, 626-629.	2.8	14

#	Article	IF	Citations
73	Pâ€glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel. International Journal of Cancer, 2013, 132, 2439-2447.	5.1	75
74	Genetically modified mouse models for oral drug absorption and disposition. Current Opinion in Pharmacology, 2013, 13, 853-858.	3.5	18
75	Murine Oatp1a/1b Uptake Transporters Control Rosuvastatin Systemic Exposure Without Affecting Its Apparent Liver Exposure. Molecular Pharmacology, 2013, 83, 919-929.	2.3	34
76	Influence of Human OATP1B1, OATP1B3, and OATP1A2 on the Pharmacokinetics of Methotrexate and Paclitaxel in Humanized Transgenic Mice. Clinical Cancer Research, 2013, 19, 821-832.	7.0	113
77	Impact of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Gene Dosage on Plasma Pharmacokinetics and Brain Accumulation of Dasatinib, Sorafenib, and Sunitinib. Journal of Pharmacology and Experimental Therapeutics, 2013, 346, 486-494.	2.5	48
78	P-glycoprotein ABCB1: a major player in drug handling by mammals. Journal of Clinical Investigation, 2013, 123, 4131-4133.	8.2	127
79	P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Restrict Brain Accumulation of the Active Sunitinib MetaboliteN-Desethyl Sunitinib. Journal of Pharmacology and Experimental Therapeutics, 2012, 341, 164-173.	2.5	36
80	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Advanced Drug Delivery Reviews, 2012, 64, 138-153.	13.7	903
81	Oral Availability and Brain Penetration of the B-RAF^{V600E} Inhibitor Vemurafenib Can Be Enhanced by the P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Inhibitor Elacridar. Molecular Pharmaceutics, 2012, 9, 3236-3245.	4.6	113
82	P-Glycoprotein, Multidrug-Resistance Associated Protein 2, Cyp3a, and Carboxylesterase Affect the Oral Availability and Metabolism of Vinorelbine. Molecular Pharmacology, 2012, 82, 636-644.	2.3	20
83	Organic Anion-Transporting Polypeptides 1a/1b Control the Hepatic Uptake of Pravastatin in Mice. Molecular Pharmaceutics, 2012, 9, 2497-2504.	4.6	24
84	Functions of OATP1A and 1B transporters in vivo: insights from mouse models. Trends in Pharmacological Sciences, 2012, 33, 100-108.	8.7	68
85	Liquid chromatographyâ€“tandem mass spectrometric assay for the ALK inhibitor crizotinib in mouse plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 905, 150-154.	2.3	23
86	Complete OATP1B1 and OATP1B3 deficiency causes human Rotor syndrome by interrupting conjugated bilirubin reuptake into the liver. Journal of Clinical Investigation, 2012, 122, 519-528.	8.2	321
87	Liquid chromatographyâ€“tandem mass spectrometric assay for the JAK2 inhibitor CYT387 in plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 895-896, 174-177.	2.3	9
88	Brain accumulation of sunitinib is restricted by Pâ€glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration. International Journal of Cancer, 2012, 130, 223-233.	5.1	145
89	A Critical Analysis of the Interplay between Cytochrome P450 3A and P-Glycoprotein: Recent Insights from Knockout and Transgenic Mice. Pharmacological Reviews, 2011, 63, 390-410.	16.0	108
90	Double-Transduced MDCKII Cells To Study Human P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) Interplay in Drug Transport across the Bloodâ^'Brain Barrier. Molecular Pharmaceutics, 2011, 8, 571-582.	4.6	63

#	Article	IF	Citations
91	A sensitive combined assay for the quantification of paclitaxel, docetaxel and ritonavir in human plasma using liquid chromatography coupled with tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2011, 879, 2984-2990.	2.3	40
92	An Integrated Pharmacokinetic Model for the Influence of CYP3A4 Expression on the In Vivo Disposition of Lopinavir and Its Modulation by Ritonavir. Journal of Pharmaceutical Sciences, 2011, 100, 2508-2515.	3.3	16
93	Differential Impact of P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) on Axitinib Brain Accumulation and Oral Plasma Pharmacokinetics. Drug Metabolism and Disposition, 2011, 39, 729-735.	3.3	62
94	Impact of Abcc2 [Multidrug Resistance-Associated Protein (Mrp) 2], Abcc3 (Mrp3), and Abcg2 (Breast) Tj ETQq0 0 0 rgBT /Overlock 10 T 7-Hydroxymethotrexate. Drug Metabolism and Disposition, 2011, 39, 1338-1344.	3.3	48
95	High Impact of Oatp1a/1b Transporters on In Vivo Disposition of the Hydrophobic Anticancer Drug Paclitaxel. Clinical Cancer Research, 2011, 17, 294-301.	7.0	49
96	P-Glycoprotein (ABCB1) Transports the Primary Active Tamoxifen Metabolites Endoxifen and 4-Hydroxytamoxifen and Restricts Their Brain Penetration. Journal of Pharmacology and Experimental Therapeutics, 2011, 337, 710-717.	2.5	68
97	Individual and combined roles of CYP3A, Pâ€glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) in the pharmacokinetics of docetaxel. International Journal of Cancer, 2010, 127, 2959-2964.	5.1	47
98	Liquid chromatography-tandem mass spectrometric assay for pravastatin and two isomeric metabolites in mouse plasma and tissue homogenates. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2010, 878, 2751-2759.	2.3	11
99	Breast Cancer Resistance Protein and P-glycoprotein Limit Sorafenib Brain Accumulation. Molecular Cancer Therapeutics, 2010, 9, 319-326.	4.1	171
100	Hepatic Clearance of Reactive Glucuronide Metabolites of Diclofenac in the Mouse Is Dependent on Multiple ATP-Binding Cassette Efflux Transporters. Molecular Pharmacology, 2010, 77, 687-694.	2.3	67
101	P-glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 Determine the Pharmacokinetics of Etoposide. Clinical Cancer Research, 2010, 16, 130-140.	7.0	79
102	Organic anion transporting polypeptide 1a/1bâ€“knockout mice provide insights into hepatic handling of bilirubin, bile acids, and drugs. Journal of Clinical Investigation, 2010, 120, 2942-2952.	8.2	191
103	Brain Accumulation of Dasatinib Is Restricted by P-Glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2) and Can Be Enhanced by Elacridar Treatment. Clinical Cancer Research, 2009, 15, 2344-2351.	7.0	158
104	Abcc2 (Mrp2), Abcc3 (Mrp3), and Abcg2 (Bcrp1) are the main determinants for rapid elimination of methotrexate and its toxic metabolite 7-hydroxymethotrexate in vivo. Molecular Cancer Therapeutics, 2009, 8, 3350-3359.	4.1	74
105	Organic Anion-Transporting Polypeptide 1B1 Mediates Transport of Gimatecan and BNP1350 and Can Be Inhibited by Several Classic ATP-Binding Cassette (ABC) B1 and/or ABCG2 Inhibitors. Drug Metabolism and Disposition, 2009, 37, 917-923.	3.3	47
106	Transport of Diclofenac by Breast Cancer Resistance Protein (ABCG2) and Stimulation of Multidrug Resistance Protein 2 (ABCC2)-Mediated Drug Transport by Diclofenac and Benzbromarone. Drug Metabolism and Disposition, 2009, 37, 129-136.	3.3	63
107	Methotrexate Pharmacokinetics in Transgenic Mice with Liver-Specific Expression of Human Organic Anion-Transporting Polypeptide 1B1 (SLCO1B1). Drug Metabolism and Disposition, 2009, 37, 277-281.	3.3	117
108	Intestinal cytochrome P450 3A plays an important role in the regulation of detoxifying systems in the liver. FASEB Journal, 2009, 23, 224-231.	0.5	42

#	Article	IF	Citations
109	Inhibition and Stimulation of Intestinal and Hepatic CYP3A Activity: Studies in Humanized CYP3A4 Transgenic Mice Using Triazolam. Drug Metabolism and Disposition, 2009, 37, 2305-2313.	3.3	61
110	Absence of Both Cytochrome P450 3A and P-glycoprotein Dramatically Increases Docetaxel Oral Bioavailability and Risk of Intestinal Toxicity. Cancer Research, 2009, 69, 8996-9002.	0.9	88
111	PXR-mediated induction of human CYP3A4 and mouse Cyp3a11 by the glucocorticoid budesonide. European Journal of Pharmaceutical Sciences, 2009, 36, 565-571.	4.0	27
112	Liquid chromatography-tandem mass spectrometric assay for the light sensitive tyrosine kinase inhibitor axitinib in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2009, 877, 4090-4096.	2.3	43
113	Physiological and pharmacological roles of ABCG2 (BCRP): Recent findings in Abcg2 knockout mice. Advanced Drug Delivery Reviews, 2009, 61, 14-25.	13.7	204
114	How important is intestinal cytochrome P450 3A metabolism?. Trends in Pharmacological Sciences, 2009, 30, 223-227.	8.7	44
115	Pharmacokinetic Assessment of Multiple ATP-binding Cassette Transporters: The Power of Combination Knockout Mice. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2009, 9, 136-145.	3.4	54
116	Midazolam Metabolism in Cytochrome P450 3A Knockout Mice Can Be Attributed to Up-Regulated CYP2C Enzymes. Molecular Pharmacology, 2008, 73, 1029-1036.	2.3	106
117	Species-Dependent Transport and Modulation Properties of Human and Mouse Multidrug Resistance Protein 2 (MRP2/Mrp2, ABCC2/Abcc2). Drug Metabolism and Disposition, 2008, 36, 631-640.	3.3	55
118	P-Glycoprotein Limits Oral Availability, Brain Penetration, and Toxicity of an Anionic Drug, the Antibiotic Salinomycin. Antimicrobial Agents and Chemotherapy, 2008, 52, 1034-1039.	3.2	53
119	Breast cancer resistance protein (Bcrp1/Abcg2) is expressed in the harderian gland and mediates transport of conjugated protoporphyrin IX. American Journal of Physiology - Cell Physiology, 2007, 292, C2204-C2212.	4.6	30
120	In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2. Molecular Cancer Therapeutics, 2007, 6, 3307-3313.	4.1	27
121	Multidrug Transporter ABCG2/Breast Cancer Resistance Protein Secretes Riboflavin (Vitamin B 2) into Milk. Molecular and Cellular Biology, 2007, 27, 1247-1253.	2.3	191
122	Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. Journal of Clinical Investigation, 2007, 117, 3583-3592.	8.2	210
123	The function of breast cancer resistance protein in epithelial barriers, stem cells and milk secretion of drugs and xenotoxins. Trends in Pharmacological Sciences, 2006, 27, 10-16.	8.7	177
124	Multidrug Resistance Protein 2 Is an Important Determinant of Paclitaxel Pharmacokinetics. Clinical Cancer Research, 2006, 12, 6125-6132.	7.0	88
125	The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. Nature Medicine, 2005, 11, 127-129.	30.7	376
126	Contribution of the ABC Transporters Bcrp1 and Mdr1a/1b to the Side Population Phenotype in Mammary Gland and Bone Marrow of Mice. Stem Cells, 2005, 23, 1059-1065.	3.2	126

#	Article	IF	Citations
127	MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid. International Journal of Cancer, 2005, 116, 824-829.	5.1	189
128	Absence of N-linked glycosylation does not affect plasma membrane localization of breast cancer resistance protein (BCRP/ABCG2). Cancer Chemotherapy and Pharmacology, 2005, 56, 344-350.	2.3	67
129	Sex-Dependent Expression and Activity of the ATP-Binding Cassette Transporter Breast Cancer Resistance Protein (BCRP/ABCG2) in Liver. Molecular Pharmacology, 2005, 67, 1765-1771.	2.3	144
130	Breast cancer resistance protein (Bcrp1/Abcg2) reduces systemic exposure of the dietary carcinogens aflatoxin B1, IQ and Trp-P-1 but also mediates their secretion into breast milk. Carcinogenesis, 2005, 27, 123-130.	2.8	132
131	The Effect of Bcrp1 (Abcg2) on the In vivo Pharmacokinetics and Brain Penetration of Imatinib Mesylate (Gleevec): Implications for the Use of Breast Cancer Resistance Protein and P-Glycoprotein Inhibitors to Enable the Brain Penetration of Imatinib in Patients. Cancer Research, 2005, 65, 2577-2582.	0.9	338
132	MIDAZOLAM AND CYCLOSPORIN A METABOLISM IN TRANSGENIC MICE WITH LIVER-SPECIFIC EXPRESSION OF HUMAN CYP3A4. Drug Metabolism and Disposition, 2005, 33, 892-895.	3.3	43
133	Human Breast Cancer Resistance Protein: Interactions with Steroid Drugs, Hormones, the Dietary Carcinogen 2-Amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and Transport of Cimetidine. Journal of Pharmacology and Experimental Therapeutics, 2005, 312, 144-152.	2.5	258
134	Mechanism of the Pharmacokinetic Interaction between Methotrexate and Benzimidazoles. Cancer Research, 2004, 64, 5804-5811.	0.9	222
135	Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Advanced Drug Delivery Reviews, 2003, 55, 3-29.	13.7	1,259
136	Evidence for Two Interacting Ligand Binding Sites in Human Multidrug Resistance Protein 2 (ATP) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	3.4	177
137	Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein. Cancer Research, 2003, 63, 1339-44.	0.9	89
138	The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. Cancer Research, 2003, 63, 6447-52.	0.9	199
139	Involvement of Organic Cation Transporter 1 in Hepatic and Intestinal Distribution of Metformin. Journal of Pharmacology and Experimental Therapeutics, 2002, 302, 510-515.	2.5	398
140	Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. Aids, 2002, 16, 2295-2301.	2.2	198
141	Polymorphisms affecting function of the human organic cation transporter hOCT1 (SLC22A1). Pharmacogenetics and Genomics, 2002, 12, 589-590.	5.7	5
142	The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 15649-15654.	7.1	759
143	Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Molecular Cancer Therapeutics, 2002, 1, 417-25.	4.1	371
144	Inhibition of BCRP-mediated drug efflux by fumitremorgin-type indolyl diketopiperazines. Bioorganic and Medicinal Chemistry Letters, 2001, 11, 29-32.	2.2	139

#	Article	IF	Citations
145	P-Glycoprotein Limits Oral Availability, Brain, and Fetal Penetration of Saquinavir Even with High Doses of Ritonavir. Molecular Pharmacology, 2001, 59, 806-813.	2.3	171
146	Reduced Hepatic Uptake and Intestinal Excretion of Organic Cations in Mice with a Targeted Disruption of the Organic Cation Transporter 1 (Oct1 [Slc22a1]) Gene. Molecular and Cellular Biology, 2001, 21, 5471-5477.	2.3	220
147	Modulation of oral bioavailability of anticancer drugs: from mouse to man. European Journal of Pharmaceutical Sciences, 2000, 12, 103-110.	4.0	125
148	Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. Aids, 2000, 14, 237-242.	2.2	164
149	Multidrug resistance protein 1 protects the choroid plexus epithelium and contributes to the blood-cerebrospinal fluid barrier. Journal of Clinical Investigation, 2000, 105, 279-285.	8.2	334
150	P-Glycoprotein, a gatekeeper in the bloodâ€“brain barrier. Advanced Drug Delivery Reviews, 1999, 36, 179-194.	13.7	821
151	Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. Journal of Clinical Investigation, 1999, 104, 1441-1447.	8.2	314
152	Hepatobiliary and intestinal clearance of amphiphilic cationic drugs in mice in which both mdr1a and mdr1b genes have been disrupted. British Journal of Pharmacology, 1998, 124, 416-424.	5.4	71
153	Availability of PSC833, a substrate and inhibitor of P-glycoproteins, in various concentrations of serum. Journal of the National Cancer Institute, 1998, 90, 1161-1166.	6.3	69
154	The physiological function of drug-transporting P-glycoproteins. Seminars in Cancer Biology, 1997, 8, 161-170.	9.6	413
155	Substantial excretion of digoxin via the intestinal mucosa and prevention of longâ€term digoxin accumulation in the brain by the mdrla Pâ€glycoprotein. British Journal of Pharmacology, 1996, 119, 1038-1044.	5.4	248
156	MDR1 P-Glycoprotein Is a Lipid Translocase of Broad Specificity, While MDR3 P-Glycoprotein Specifically Translocates Phosphatidylcholine. Cell, 1996, 87, 507-517.	28.9	858
157	The human MDR3 P-glycoprotein promotes translocation of phosphatidylcholine through the plasma membrane of fibroblasts from transgenic mice. FEBS Letters, 1994, 354, 263-266.	2.8	260